Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
A Randomized, Double-blind, Placebo-controlled, Single Dose, Two-period, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of AMG 811 in Subjects With Discoid Lupus Erythematosus
Sponsor: Amgen
Terminated
The 16 subjects enrolled in the study should enable Amgen to adequately assess safety and tolerabili
Listed as NCT01164917, this PHASE1 trial focuses on Cutaneous Lupus and Discoid Lupus and remains terminated or withdrawn. Sponsored by Amgen, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE1
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .